Tusk Therapeutics appoints Matthew Hall as Chief Financial Officer

London and Stevenage, UK – 14 September 2017: Tusk Therapeutics, an immuno-oncology company, is pleased to announce the appointment of Matthew Hall as Chief Financial Officer. Matthew is a seasoned finance professional with over 20 years’ corporate finance experience in a number of leading organisations and fast growing companies.  Most recently Chief Financial Officer at Simbec-Orion Group, Matthew has extensive … Read More

Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies

​London and Stevenage, United Kingdom CANCER RESEARCH TECHNOLOGY, Cancer Research UK’s commercial arm, Tusk Therapeutics, an immuno-oncology company and UCL (University College London) have signed a licence and collaboration agreement to research, develop and commercialise an antibody-based therapeutic against a target that plays a key role in immune suppression in cancer. ​ Under the terms of the agreement, Tusk Therapeutics … Read More